Polymorphisms in two genes, IL-1B and ACE, are associated with erythropoietin resistance in Korean patients on maintenance hemodialysis

Experimental and Molecular Medicine

Volumn 40, Issue 2, 2008, Pages 161-166

  Jeong, Kyung Hwan ^a   Lee, Tae Won ^a   Ihm, Chun Gyoo ^a   Lee, Sang Ho ^a   Moon, Ju Young ^a  

^a Kyung Hee University Hospital   (South Korea)

Author keywords

Chronic; End stage renal disease; Erythropoietin; Interleukin 1 ; Kidney failure; Peptidyl dipeptidase A; Polymorphism, genetic

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FERRITIN; HEMOGLOBIN; PARATHYROID HORMONE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; ALLELE; ANEMIA; ANGIOTENSIN CONVERTING ENZYME GENE; ARTICLE; DIABETES MELLITUS; DRUG DOSE TITRATION; FEMALE; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC MARKER; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INTERLEUKIN 1BETA GENE; KIDNEY FAILURE; KOREA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 44349158955     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.3858/emm.2008.40.2.161     Document Type: Article

References (23)

1. Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J Am Soc Nephrol 2003;14:1776-84
2. Danielson B. R-HuEPO hyporesponsiveness-who and why? Nephrol Dial Transplant 1995;10 Suppl 2:69-73
3. Danilov S, Savoie F, Lenoir B, Jeunemaitre X, Azizi M, Tarnow L, Alhenc-Gelas F. Development of enzyme-linked immunoassays for human angiotensin I converting enzyme suitable for large-scale studies. J Hypertens 1996;14:719-27
4. di Giovine FS, Takhsh E, Blakemore AI, Duff GW. Single base polymorphism at -511 in the human interleukin-1 beta gene (IL-1 beta). Hum Mol Genet 1992;1:450
5. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147
6. Hatano M, Yoshida T, Mimuro T, Kimata N, Tsuchiya K, Sanaka T, Nihei H. The effects of ACE inhibitor treatment and ACE gene polymorphism on erythropoiesis in chronic hemodialysis patients. Nippon Jinzo Gakkai Shi 2000;42:632-9
7. Hurme M, Lahdenpohja N, Santtila S. Gene polymorphisms of interleukins 1 and 10 in infectious and autoimmune diseases. Ann Med 1998;30:469-73
8. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998;18:555-9
9. Maury CP, Liljestrom M, Laiho K, Tiitinen S, Kaarela K, Hurme M. Anaemia of chronic disease in AA amyloidosis is associated with allele 2 of the interleukin-1beta-511 promoter gene and raised levels of interleukin-1beta and interleukin-18. J Intern Med 2004;256:145-52
10. Means RT Jr, Krantz SB. Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by recombinant human erythropoietin. Blood 1991;78:2564-7
11. Means RT Jr, Krantz SB. Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. J Clin Invest 1993;91:416-9
12. Mrug M, Stopka T, Julian BA, Prchal JF, Prchal JT. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997;100:2310-4
13. Muirhead N, Hodsman AB. Occult infection and resistance of anaemia to rHuEpo therapy in renal failure. Nephrol Dial Transplant 1990;5:232-4
14. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-6
15. Priyadarshi A, Shapiro JI. Erythropoietin resistance in the treatment of the anemia of chronic renal failure. Semin Dial 2006;19:273-8
16. Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 1993;328:171-5
17. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-6
18. Schaefer RM, Horl WH, Massry SG. Treatment of renal anemia with recombinant human erythropoietin. Am J Nephrol 1989;9:353-62
19. Schardin KE. Case management of the anemic patient. Epoetin alfa: focus on inflammation and infection. Anna J 1990;17:468-9
20. Sharples EJ, Varagunam M, Sinnott PJ, McCloskey DJ, Raftery MJ, Yaqoob MM. The effect of proinflammatory cytokine gene and angiotensin-converting enzyme polymorphisms on erythropoietin requirements in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 2006;26:64-8
21. Tarng DC, Chen TW, Huang TP. Iron metabolism indices for early prediction of the response and resistance to erythropoietin therapy in maintenance hemodialysis patients. Am J Nephrol 1995;15:230-7
22. Varagunam M, McCloskey DJ, Sinnott PJ, Raftery MJ, Yaqoob MM. Angiotensin-converting enzyme gene polymorphism and erythropoietin requirement. Perit Dial Int 2003;23:111-5
23. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986;2:1175-8